top of page

Lung Transplant



People living with a lung transplant
in the US


5-year survival rate of transplant patients


ARINA·1 has been shown to downregulate the inflammation associated with the development and progression of bronchiolitis obliterans syndrome (BOS) in a lung transplant, which is the leading cause of death in people with a lung transplant. The therapy has the potential to meet an immense unmet need to improve pulmonary function, quality of life, and overall clinical outcomes in people with early BOS following lung transplant. 


Lung transplant recipients have the lowest long-term success rate of all solid organ transplants. There is an urgent need in individuals with a lung transplant for therapies that promote the clearance of pathogens from the airways and decrease pathological inflammation, while not leaving a patient susceptible to infection. Approximately 2,500 lung transplants are performed annually and approximately 20,000 people live with a lung transplant in the US. Despite slight improvements in survival rates, the 5-year survival rate remains at 60%, the lowest survival rate of all solid organ transplants. There are currently no FDA-approved therapies for treating BOS progression in a lung transplant.

Current Status

Phase 3 Clinical Trial

Prevention of BOS Progression

Primary Endpoint:

Improvement of 7% in FEV1 compared to the control arm.

Secondary Endpoints:

Quality of life, time to augmented immunosuppression, use of augmented immunosuppression, FVC, FEF25-75%


48 weeks (Primary Endpoint at 24 weeks)

Trial Number:


Patient Enrollment Status

Starts Dec. 2022

Est. NDA Filling Date



Other Target Indications for ARINA·1

bottom of page